ramipril,atorvastatin
Pfizer
['congrat']
24% reduction in the primary endpoint in the secure trial with the cnic polypill! excellent presentation by congrats to all the team and especially my good friend jos mar a castellano (copi and first author of the publication in )
#esccongress 
Interventional cardiologist. Cardiology, Hospital Universitario de San Juan Alicante. Spain